Prelude Capital Management’s Cabaletta Bio CABA Stock Holding History

Prelude Capital Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.4K	Sell	10,089 -33,327	-77%	-$110K	﹤0.01%	1186
2026 Q1	$117K	Buy	+43,416	New	+$121K	0.01%	1026
2025 Q1	–	Sell	-11,001	Closed	-$25K	–	1219
2024 Q4	$25K	Buy	+11,001	New	+$38.6K	﹤0.01%	1171
2024 Q3	–	Sell	-95,200	Closed	-$712K	–	1297
2024 Q2	$712K	Buy	+95,200	New	+$1.17M	0.05%	396
2024 Q1	–	Sell	-11,100	Closed	-$252K	–	1328
2023 Q4	$252K	Buy	+11,100	New	+$187K	0.02%	831

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Prelude Capital Management's CABA Position: Q2 2026 in Review

Prelude Capital Management reduced its Cabaletta Bio (CABA) stake by 77% in Q2 2026, selling an estimated $110K and leaving 10,089 shares worth $31.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1186.

Prelude Capital Management first reported a position in CABA in Q4 2023 and has held it in 5 quarters since. The position peaked at $712K in Q2 2024. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

Prelude Capital Management held 10,089 shares of Cabaletta Bio worth $31.4K as of Q2 2026.
Prelude Capital Management sold 33,327 Cabaletta Bio shares in Q2 2026, an estimated $110K.
Cabaletta Bio made up ﹤0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1186 holding.
Prelude Capital Management first reported a position in Cabaletta Bio in Q4 2023 and has held it in 5 quarters since.
Prelude Capital Management's Cabaletta Bio position peaked at $712K in Q2 2024.
140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.